Recombinant MAPT (Tilavonemab Biosimilar) antibody
The Humanized Chimeric anti-MAPT (Tilavonemab Biosimilar) antibody is suitable to detect MAPT (Tilavonemab Biosimilar) in samples from Human. It has been validated for ELISA and WB.
Catalog No. ABIN7538070
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant MAPT (Tilavonemab Biosimilar) antibody (ABIN7538070)
Target
MAPT (Tilavonemab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Chimeric
Conjugate
This MAPT (Tilavonemab Biosimilar) antibody is un-conjugated
Application
ELISA, Western Blotting (WB)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Tilavonemab Biosimilar - Anti-MAPT mAb - Research Grade
-
Characteristics
- Antibody Type: IgG4-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Purity
- > 85%
-
Isotype
- IgG4
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- MAPT (Tilavonemab Biosimilar)
-
Target Type
- Biosimilar
-
Background
- Tilavonemab is a humanised anti-tau antibody that binds amino acids 25-30 near the N-terminal end of the tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates and reduces brain atrophy. Tilavonemab can be used in the study of Alzheimer's disease.
-
CAS-No
- 2096513-89-0
Target
-
You are here:
